vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and WORKIVA INC (WK). Click either name above to swap in a different company.
WORKIVA INC is the larger business by last-quarter revenue ($238.9M vs $139.2M, roughly 1.7× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 4.9%, a 30.5% gap on every dollar of revenue. On growth, WORKIVA INC posted the faster year-over-year revenue change (19.5% vs 18.4%). WORKIVA INC produced more free cash flow last quarter ($50.7M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 16.6%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Workiva, Inc. is a global software-as-a-service (SaaS) company. It provides a cloud-based connected and reporting compliance platform that enables the use of connected data and automation of reporting across finance, accounting, risk, and compliance.
ADMA vs WK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $238.9M |
| Net Profit | $49.4M | $11.8M |
| Gross Margin | 63.8% | 80.7% |
| Operating Margin | 45.1% | 3.3% |
| Net Margin | 35.5% | 4.9% |
| Revenue YoY | 18.4% | 19.5% |
| Net Profit YoY | -55.9% | 234.0% |
| EPS (diluted) | $0.20 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $238.9M | ||
| Q3 25 | $134.2M | $224.2M | ||
| Q2 25 | $122.0M | $215.2M | ||
| Q1 25 | $114.8M | $206.3M | ||
| Q4 24 | $117.5M | $199.9M | ||
| Q3 24 | $119.8M | $185.6M | ||
| Q2 24 | $107.2M | $177.5M | ||
| Q1 24 | $81.9M | $175.7M |
| Q4 25 | $49.4M | $11.8M | ||
| Q3 25 | $36.4M | $2.8M | ||
| Q2 25 | $34.2M | $-19.4M | ||
| Q1 25 | $26.9M | $-21.4M | ||
| Q4 24 | $111.9M | $-8.8M | ||
| Q3 24 | $35.9M | $-17.0M | ||
| Q2 24 | $32.1M | $-17.5M | ||
| Q1 24 | $17.8M | $-11.7M |
| Q4 25 | 63.8% | 80.7% | ||
| Q3 25 | 56.3% | 79.3% | ||
| Q2 25 | 55.1% | 77.0% | ||
| Q1 25 | 53.2% | 76.6% | ||
| Q4 24 | 53.9% | 77.1% | ||
| Q3 24 | 49.8% | 76.5% | ||
| Q2 24 | 53.6% | 76.8% | ||
| Q1 24 | 47.8% | 76.4% |
| Q4 25 | 45.1% | 3.3% | ||
| Q3 25 | 38.0% | -1.5% | ||
| Q2 25 | 35.1% | -10.3% | ||
| Q1 25 | 30.4% | -12.0% | ||
| Q4 24 | 32.6% | -6.7% | ||
| Q3 24 | 33.1% | -11.7% | ||
| Q2 24 | 36.6% | -13.0% | ||
| Q1 24 | 26.7% | -10.4% |
| Q4 25 | 35.5% | 4.9% | ||
| Q3 25 | 27.1% | 1.2% | ||
| Q2 25 | 28.1% | -9.0% | ||
| Q1 25 | 23.4% | -10.4% | ||
| Q4 24 | 95.2% | -4.4% | ||
| Q3 24 | 30.0% | -9.2% | ||
| Q2 24 | 29.9% | -9.9% | ||
| Q1 24 | 21.7% | -6.7% |
| Q4 25 | $0.20 | $0.21 | ||
| Q3 25 | $0.15 | $0.05 | ||
| Q2 25 | $0.14 | $-0.35 | ||
| Q1 25 | $0.11 | $-0.38 | ||
| Q4 24 | $0.45 | $-0.15 | ||
| Q3 24 | $0.15 | $-0.31 | ||
| Q2 24 | $0.13 | $-0.32 | ||
| Q1 24 | $0.08 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $338.8M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $-5.4M |
| Total Assets | $624.2M | $1.5B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $338.8M | ||
| Q3 25 | $61.4M | $315.9M | ||
| Q2 25 | $90.3M | $284.3M | ||
| Q1 25 | $71.6M | $242.0M | ||
| Q4 24 | $103.1M | $301.8M | ||
| Q3 24 | $86.7M | $248.2M | ||
| Q2 24 | $88.2M | $267.9M | ||
| Q1 24 | $45.3M | $296.1M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $-5.4M | ||
| Q3 25 | $431.2M | $-36.9M | ||
| Q2 25 | $398.3M | $-66.5M | ||
| Q1 25 | $373.4M | $-75.7M | ||
| Q4 24 | $349.0M | $-41.7M | ||
| Q3 24 | $231.9M | $-50.8M | ||
| Q2 24 | $188.3M | $-77.7M | ||
| Q1 24 | $153.7M | $-83.2M |
| Q4 25 | $624.2M | $1.5B | ||
| Q3 25 | $568.7M | $1.4B | ||
| Q2 25 | $558.4M | $1.3B | ||
| Q1 25 | $510.6M | $1.3B | ||
| Q4 24 | $488.7M | $1.4B | ||
| Q3 24 | $390.6M | $1.3B | ||
| Q2 24 | $376.4M | $1.2B | ||
| Q1 24 | $350.9M | $1.2B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $51.0M |
| Free Cash FlowOCF − Capex | $34.6M | $50.7M |
| FCF MarginFCF / Revenue | 24.8% | 21.2% |
| Capex IntensityCapex / Revenue | 0.8% | 0.1% |
| Cash ConversionOCF / Net Profit | 0.72× | 4.31× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $138.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $51.0M | ||
| Q3 25 | $13.3M | $46.2M | ||
| Q2 25 | $21.1M | $50.3M | ||
| Q1 25 | $-19.7M | $-7.4M | ||
| Q4 24 | $50.2M | $44.0M | ||
| Q3 24 | $25.0M | $18.9M | ||
| Q2 24 | $45.6M | $-14.0K | ||
| Q1 24 | $-2.2M | $24.8M |
| Q4 25 | $34.6M | $50.7M | ||
| Q3 25 | $-1.1M | $46.1M | ||
| Q2 25 | $18.7M | $49.3M | ||
| Q1 25 | $-24.4M | $-8.1M | ||
| Q4 24 | $47.5M | $43.2M | ||
| Q3 24 | $24.0M | $18.7M | ||
| Q2 24 | $43.6M | $-122.0K | ||
| Q1 24 | $-4.6M | $24.6M |
| Q4 25 | 24.8% | 21.2% | ||
| Q3 25 | -0.8% | 20.5% | ||
| Q2 25 | 15.3% | 22.9% | ||
| Q1 25 | -21.2% | -3.9% | ||
| Q4 24 | 40.4% | 21.6% | ||
| Q3 24 | 20.0% | 10.1% | ||
| Q2 24 | 40.7% | -0.1% | ||
| Q1 24 | -5.6% | 14.0% |
| Q4 25 | 0.8% | 0.1% | ||
| Q3 25 | 10.7% | 0.0% | ||
| Q2 25 | 2.0% | 0.5% | ||
| Q1 25 | 4.1% | 0.4% | ||
| Q4 24 | 2.3% | 0.4% | ||
| Q3 24 | 0.9% | 0.1% | ||
| Q2 24 | 1.9% | 0.1% | ||
| Q1 24 | 2.9% | 0.1% |
| Q4 25 | 0.72× | 4.31× | ||
| Q3 25 | 0.36× | 16.57× | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
WK
| License And Service | $219.3M | 92% |
| XBRL Professional Services | $16.4M | 7% |
| Other Services | $3.2M | 1% |
